Objective. The objective of this study was to determine if the
INTRODUCTION
The aberrant regulation of tyrosine phosphorylation is necessary for, or often associated with, the initiation and progression of various cancers, with a large fraction of oncogenes representing protein tyrosine kinases (PTK), regulators of tyrosine kinases, or targets/substrates of tyrosine kinases. In human ovarian and breast cancers, the mechanism of aberrant PTK activation in a significant fraction of cancers is overexpression of receptor PTKs (rPTK), as in the case of the EGFR and HER-2/neu rPTKs. In human ovarian cancer cases, the observed overexpression is often, but not always, attributable to amplification of an rPTK gene, such as HER-2/neu, FGR-R, or c-met (reviewed in [1] ). In contrast, the unregulated activation of nonreceptor (nr) PTKs, e.g., Src, is attributable to overexpression of the protein in the absence of gene amplification, or dephosphorylation of regulatory residues, resulting in constitutive activation [2] . Increased expression and/or activity of various Src family PTKs has been associated with the development of a number of human cancers, including colon, pancreatic, and breast cancers [3] [4] [5] [6] [7] . Although increased Src expression and activity is associated with malignancy in these cancers, elucidation of the biological function(s) of Src overexpression and activation remains incomplete, possibly due to the large number of growth-regulatory processes in which Src participates [8] . Src directly associates with, and may regulate signaling via, the EGFR and HER-2/neu receptor PTKs [9 -11] , both of which are involved in ovarian cancer tumorigenesis [1] . Nevertheless, whether Src is involved in the aberrant signaling mediated by the altered expression of these receptors in ovarian cancer biology remains unknown. In this report, we assessed Src expression and activation in the epithelium of normal human ovaries and late-stage ovarian tumors, as well as in a panel of cultured normal human ovarian epithelial cells (NOE) and established human ovarian cancer cell lines in vitro. Our results demonstrate that Src is overexpressed in the majority of late-stage ovarian tumors and cancer cell lines, and is frequently, although not exclusively, associated with HER-2/neu overexpression.
METHODS

Reagents
The sheep polyclonal antibody (pAb) to Src (SI4045; Affiniti Research Products Limited, Exeter, UK) was used for immunohistochemical detection of total Src protein in paraffinembedded human tissue sections [5, 7] 
Cell Culture
HT29 human colon adenocarcinoma cells (a positive control cell line for Src activation) were obtained from the American Type Culture Collection (ATCC, Rockville, MD) and maintained in Dulbecco's minimal essential medium (DMEM) with Earle's salts and 2 mM L-glutamine (GIBCO-Life Technologies, Inc., Grand Island, NY) supplemented with 10% fetal bovine serum (FBS; Hyclone Laboratories, Inc., Logan, UT). NOE cells were acquired from freshly isolated normal human ovaries removed at hysterectomy and cultured for up to three passages in 1:1 MCDB105 (Sigma, St. Louis, MO):Medium 199 (GIBCO) containing 2 mM L-glutamine, 10% FBS, and 10 ng/mL epidermal growth factor (EGF, Sigma) as previously described [14] . Immortalized human normal ovarian surface epithelium (IOSE), clones 29 and 80 were a generous gift of Dr. N. Auersperg, University of British Columbia, Vancouver, Canada, and were cultured in 1:1 MCDB105: Medium 199 containing 2 mM L-glutamine and 5% FBS. SKOv-3 human ovarian cancer cells were obtained from the ATCC and cultured in McCoys 5A (GIBCO) containing 2 mM L-glutamine and 10% FBS. The OVCA 420, 429, and 433 ovarian cancer cell lines, originally established from malignant ascites tumor cells from ovarian cancer patients [15] , were maintained in DMEM containing 10% FBS. The OVCAR-3 (ATCC) and HEY (a generous gift of Dr. G. B. Mills, M.D. Anderson Cancer Center) ovarian cancer cell lines were maintained in RPMI 1640 medium containing 10% FBS. All cells were maintained at 37°C in a humidified atmosphere containing 5% CO 2 . Cells were routinely tested to ensure freedom from mycoplasma contamination.
Immune Complex Kinase Assay
Monolayer cells in the logarithmic phase of growth (ϳ70% confluency) were rinsed twice with ice-cold phosphate-buffered saline (PBS; GIBCO) prior to detergent lysis in modified RIPA assay buffer containing 20 mM phosphate, pH 7.4, 1% Triton X-100, 150 mM NaCl, 5mM EDTA, 50 mM NaF, protease inhibitors, and 2 mM sodium orthovanadate. Clarified lysate supernatants (250 g total protein) were reacted with 2-4 g of either MAb327 or MAb1B7 primary antibodies. Immune complexes formed by the addition of rabbit antimouse IgG and 10% (v/v) Pansorbin were subjected to immune complex kinase assays (ICKA) performed as previously described [16] . ICKA reactions were terminated by the addition of Laemmli SDS sample-loading buffer, and labeled proteins were separated by electrophoresis on 8% SDS-polyacrylamide gels (PAGE) prior to autoradiography.
Immunoblotting
Clarified cell lysates from cell monolayers in the logorithmic phase of growth were separated (25 ug/lane) on 10% SDS-PAGE and electroblotted onto polyvinylidene difluoride (PVDF) Immobilon membranes (Amersham). Membranes were blocked with PBS containing 15% skim milk, and then incubated with anti-Src (MAb 327) or anti-Yes (MAb 1B7) antibodies at 4°C for 12 h. The membranes were then incubated with horseradish peroxidase-conjugated rabbit antimouse IgG secondary antibodies (1:3000) for 2 h at 37°C prior to detection using the ECL system (Amersham).
Immunohistochemistry
Paraffin-embedded human ovarian tumors were selected from the ovarian tissue bank compiled at the University of Texas M.D. Anderson Cancer Center, and verified as late-stage primary ovarian tumors by pathological examination. Analyses of total Src and Yes expression in paraffin-embedded human ovarian tumor sections were performed as described [5, 7] with slight modifications. Briefly, 4-m tissue sections were deparaffinized and the endogenous peroxidase activity was quenched with 0.2% H 2 O 2 in methanol. Following rehydration, nonspecific binding was blocked with 1% bovine serum albumin (BSA), and the sections then incubated for 1 h with MAb327 diluted in PBS containing 0.5% BSA. Following extensive washing with PBS containing 0.05% Tween 20, rabbit antisheep peroxidase-coupled secondary antibody, and 1 mg/mL diaminobenzidine in 0.02% H 2 O 2 were used to detect binding of the primary antibodies. Tissue sections were counterstained with hematoxylin. Staining of tissue sections for epithelial cytokeratin was performed using the AE1/AE3 antibody cocktail (Boehringer-Mannheim, Indianapolis, IN), and HER-2/neu staining was performed using anti-c-erbB-2 antibody (Zymed Laboratories, San Francisco, CA), both according to procedures recommended by the manufacturer.
Staining for the active form of Src in tissue sections using MAb clone 28 was performed as described [13] . Briefly, sections were deparaffinized, incubated with PBS containing 5% normal goat serum to block nonspecific protein binding, and then pretreated with the biotin/avidin blocking kit (Vector Laboratories, Inc.) to block avidin binding to endogenous biotin. Undiluted MAb clone 28 clarified hybridoma superna-tant was then incubated with the tissues at 4°C for 16 h. Primary antibody binding was detected using biotinylated goat anti-mouse IgG, peroxidase-conjugated streptavidin, and diaminobenzidine prior to counterstaining with hematoxylin.
Paraffin-embedded logarithmic-phase HT-29 cells or SKOv-3 ovarian cancer cells were used as the positive control for Src, Yes, and activated Src histochemical staining, and paraffin-embedded NIH-3T3 cells or NOE cells were used as the negative control for Yes and Src histochemical staining, while the negative control for MAb clone 28 staining was normal mouse IgG. Staining was performed on tumor tissue sections using dilutions of primary antibody that optimally distinguished positive and negative controls.
Statistical Methods
Differences in Src expression between normal ovarian epithelium versus late-stage ovarian cancer were evaluated using the Wilcoxon-Mann-Whitney test. Association between Src and HER-2/neu expression in ovarian tumors was evaluated by a generalized Fisher exact test.
RESULTS
Src and Yes Expression and Activation in Cultured Ovarian Epithelium
To begin to assess Src activation during ovarian cancer pathogenesis, comparative analyses of Src expression and intrinsic tyrosine kinase activity in cultured NOE, nontumorigenic SV40 large T-immortalized NOE (IOSE) and established ovarian cancer cells in vitro were performed. Figure 1 illustrates that Src protein expression and intrinsic kinase activity are quite low in cultured NOE cells, while protein expression is slightly increased in cultured IOSE cells, although intrinsic kinase enzyme activity remains low. In contrast, the expression of Src protein is increased demonstrably in five of six (ϳ83%) malignant ovarian cancer cell lines, with a corresponding increase in Src tyrosine kinase specific activity in four of the five overexpressors ( Fig. 1 and Table 1) .
As Src and Yes are generally expressed in similar tissues, we also assessed Yes expression and tyrosine kinase activation in the panel of established cell lines. Similar to our findings with Src, the protein expression of Yes is very low in normal ovarian epithelium, but increased in six of six (100%) ovarian cancer cell lines. In contrast to Src, Yes relative specific activity was variant in the two NOE lines, being quite low in only one of the two normal cell lines evaluated, but in both IOSE lines. Simple observation of Fig. 1 resulted in the initial conclusion that Yes specific activity was higher in the cancer cell lines. However, due to the variance of the Yes activity in the NOE lines, the average activity of Yes in the two NOE lines was utilized for comparison with the activity of Yes in each of the ovarian cancer cell lines. This resulted in the conclusion that relative Yes activity was high in only the SKOv3 cell line ( Fig. 1 and Table 1 ). These results suggest that, in general, Src and Yes protein overexpression occurs in cultured human ovarian cancer cell lines. However, for Src, overexpression of protein nearly always resulted in increased kinase activation, while for Yes, overexpression of the protein rarely resulted in increased kinase activation.
FIG. 1. Src and Yes
Western analysis and immune complex kinase assay on a panel of normal and malignant ovarian epithelial cell lines. Src and Yes expression was assessed by immunoblot analysis, and activation status was determined by immunoprecipitation and the in-gel kinase assay, as described under Materials and Methods. NOE, normal ovarian epithelium; IOSE, immortalized ovarian surface epithelium. Further, the results suggest that Src activation does not occur in the early stages of oncogenic cellular transformation, i.e., during immortalization of normal ovarian epithelium, but rather at a later stage in the process.
Src Overexpression in Late-Stage Ovarian Tumors
In several model systems for human cancers, the Src tyrosine kinase has been found to be more important than the Yes tyrosine kinase [17, 18] . Indeed, in SKOv-3 cells, we have shown that antisense-specific reduction of Src activity but not Yes activity caused a dramatic reduction in tumorigenic capability and microvasculature [13] . Therefore, for the present studies we elected to concentrate further efforts on the expression of Src in human ovarian tumors. To establish the validity of antibody usage for immunohistochemical analyses on human tissue sections, we stained paraffin-embedded cultured SKOv-3 (positive control) and NOE-032 (negative control) cells for total Src expression. Pan-Src staining with polyclonal pABSrc revealed no significant staining in the cytoplasm of cultured NOE cells, but overexpression of Src in the cytoplasm of cultured SKOv-3 cells (data not shown), in agreement with the immunoblot analyses.
Fifteen ovarian tumors, all derived from patients with primary epithelial ovarian cancer, and 3 normal ovaries, were selected from the ovarian tissue bank at the University of Texas M.D. Anderson Cancer Center in accordance with Institutional guidelines, and utilized for immunohistochemical analysis of Src expression and activation. Characterization of the pathology of the tumors indicated that 11 tumors were Grade III/ Stage IV, 2 tumors were Grade III-IV/Stage IV, and 1 tumor each Grade III/Stage IIIC or Grade II/Stage IV. Histologically, the tumors were subtyped as papillary serous (11) or serous (4) lesions. The median age of the patients was 70 years (range 41-93). The median survival times for patients with gross and minimal residual disease following initial debulking was 19.5 and 30.5 months, respectively. At the time of analysis, 1 patient was alive with disease, while the remaining 14 had died of disease.
A compilation of the staining data for pan-Src expression (Table 2) revealed that, in agreement with immunoblot and kinase activity assays, normal ovarian epithelium had immunohistochemically minimal or undetectable Src expression (Figure 2 ). In contrast, 14 of 15 tumors displayed pan-Src expression that exceeded the expression observed in normal epithelium (Table 2 and Figure 2) , with eight of the tumors displaying 2-3ϩ Src overexpression. The expression of Src as revealed by pan-Src staining did not appear to be limited to the cytoplasmic membrane (in contrast to activated Src, see below). No pattern of differential Src overexpression could be discerned between papillary serous and serous tumors. Src overexpression was significantly higher in metastatic ovarian cancer when compared with normal ovarian surface epithelium (p Յ 0.0037). These results indicate that Src is overexpressed in a large fraction of metastatic human ovarian tumors.
Overexpressed Src Is Activated in Ovarian Tumors
The activity of human Src is inhibited by phosphorylation at tyrosine 530 (Tyr 530 ; reviewed in [8] ; avian Src Tyr 527 ) in the C-terminal regulatory domain of Src. To assess whether overexpressed Src observed in ovarian tumors was in an activated state, we utilized a recently developed monoclonal antibody (Clone 28; a generous gift of Dr. M. K. Owada, Kyoto Pharmaceutical University) which specifically reacts with an epitope surrounding the nonphosphorylated Tyr 530 , and thus only with the activated form of Src [13] . This antibody has been used to detect activated Src in early colonic neoplasms [19] .
Immunohistochemical staining of the ovarian tumors with the most dramatic overexpression of Src (2-3ϩ) for activated Src using Clone 28 MAb revealed that 7/8 2-3ϩ tumors displayed intense staining for the activated form of Src (Table  2 and Figure 2 ), while control staining for activated Src in cells which did not overexpress Src displayed very weak Clone 28 a Staining intensity was evaluated on a 0 -3ϩ increasing scale, with 0 equivalent to negative control staining in the absence of primary antibody.
b Immunohistochemical staining performed as described under Materials and Methods. Pan-Src stain using pAbSrc (Affiniti SI4045); activated Src stain using Clone 28 MAb.
c Total number of tissues or tumors stained. d Total number of cases of pan-Src staining elected for activated Src staining.
e Not done.
staining (data not shown). Heterogeneity for activated Src was observed within the tumors, although a large fraction of cells in each tumor that overexpressed Src also displayed activated Src.
In agreement with the hypothesis that Src, at least in part, functions by mediating signaling through growth factor receptor tyrosine kinases, including the EGFR and HER-2/neu receptors [9, 11, 20, 21] , we observed activated Src staining at the cytoplasmic membrane of tumor cells, but additionally in some perinuclear regions. These data indicated that at least a large fraction of the Src which was overexpressed in ovarian tumors was in the activated form, and suggests that both the overexpression and activation of Src are involved in ovarian tumorigenesis.
HER-2/neu and Src Overexpression in Ovarian Tumors
Amplification and/or overexpression of the HER-2/neu receptor tyrosine kinase is a common molecular alteration in a large fraction (25-30%) of human ovarian tumors (reviewed in [1] ). In human ovarian and breast cancers, HER-2/neu overexpression is associated with reduced disease-free survival, increased drug resistance, and increased metastatic potential [22] [23] [24] [25] . Since Src can physically associate with the cytoplasmic domains of the EGFR and HER-2/neu receptors [9 -11] and perhaps modulate signaling through these receptors [11, 21, 26] , we investigated whether Src overexpression was concordant with the overexpression of one of these proteins, HER-2/ neu, in the panel of ovarian tumors used for this study. All 3 normal ovaries displayed epithelium with low or undetectable levels of Src and low or undetectable levels of HER-2/neu (see Fig. 2 ). In the 15 tumors, there was no significant association between the expression levels of HER-2/neu and Src (P ϭ 0.71). However, 5 of 15 tumors (33%) had both low (0 or 1ϩ) HER-2/neu and low Src expression, and similarly 4 of 15 tumors (27%) had high (2ϩ or 3ϩ) expression levels of both proteins (see Fig. 2 ). Thus when the expression of the Src and HER-2/neu proteins was dichotomized as low expression (0 -1ϩ) versus high expression (2-3ϩ), 60% of the tumors displayed concordant coexpression of the two proteins.
DISCUSSION
In this communication we report that the overexpression of activated Src is a frequent molecular alteration in late-stage human ovarian tumors. Our results suggest that Src overexpression and activation occur subsequent to immortalization of ovarian epithelium, and that Src may be involved in the biology of human ovarian tumors. We further showed that Src overexpression, although apparently concordant with HER-2/ neu overexpression in a majority of cases, did not display a statistical association in the sample of 15 human ovarian tumors examined.
Our observation that Src overexpression was not statistically significantly associated with HER-2/neu overexpression in tumors was due, at least in part, to Src overexpression when HER-2/neu expression was at a normal level. Of the 15 tumors examined, the results in 9 (60%) support a concordant associ- ation between the levels of expression of the two proteins. Specifically, 5 tumors (33%) displayed high Src/high Her-2/ neu, and 4 tumors (27%) displayed low Src/low HER-2/neu, for a total of 60% concordance. In contrast, 3 tumors (20%) displayed high Src in the absence of Her-2/neu overexpression, which may be explained by the possibility that the expression of Src is also dependent on the expression of other rPTKs, e.g., EGFR, which may play a role in ovarian cancer biology [1] . Similar results have been observed in breast cancer, where 80% of tumors have activated Src, but only 30% have amplified or overexpressed HER-2/neu [22] . Indeed, since Src associates directly with a variety of receptor tyrosine kinases, it is not surprising to observe a larger number of tumors displaying Src overexpression than HER-2/neu overexpression.
We have reported recently that Src overexpression and activation in human ovarian epithelial cancer cells are not epigenetic changes without relevance to tumor growth, but are instead critical for ovarian tumorigenesis, since reduction of Src expression and activity by antisense methodology in the SKOv-3 model late-stage cell line dramatically reduced anchorage-independent growth in vitro, and tumor development and vascularization when inoculated into nude mice in vivo [12] . In contrast, the generation of Src antisense clones in the 2774-C10 human ovarian cancer cell line, which expresses normal levels of HER-2/neu on the cell surface, resulted in only slightly decreased, and not statistically significant, anchorage-independent growth in vitro (J.R.W., unpublished observation). These results suggest that Src activation may contribute to oncogenic potential in human ovarian epithelium in the context of overexpression of a receptor PTK such as the HER-2/neu. Our results also infer further increases in Src activation in metastases derived from primary ovarian cancers, in agreement with similar studies in human colon cancer, in which Src is activated at later stages and correlates with tumor prognosis [27] .
In summary, we have shown that the Src PTK is overexpressed and activated in both human ovarian tumors and ovarian cancer cells in vitro. The overexpression of Src may be functionally associated with Her-2/neu overexpression, although Src overexpression may also occur in the context of the overexpression of other functionally important receptor PTKs.
